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A 38-year-old woman presented with progressive metastatic World Health Organization (WHO) subtype B1 thymoma 
after previous cisplatin-based chemotherapy, mediastinal radi-
ation, and pemetrexed. She enrolled on a phase II trial of cixu-
tumumab, an insulin-like growth factor-1 receptor antibody 
(20 mg/kg, intravenously q 3 weeks).1
After two doses, a 29% reduction in the sum of the tar-
get lesions was observed. Three weeks after the third dose, she 
presented with fatigue, dyspnea, dysphagia, and dysphonia. 
She had grade 4 proximal muscle weakness of extremities and 
neck with generalized hyporeflexia. Investigations (Table 1) 
revealed severe multi-organ dysfunction with polymyositis, 
fascitis, myocarditis, hepatitis, hypogammaglobulinemia, 
and possible bulbar myasthenic involvement. A day later, she 
developed worsening of the bulbar symptoms and respira-
tory failure necessitating noninvasive ventilation. She was 
treated with immunoglobulin and methylprednisolone and 
responded rapidly with marked improvement in respiratory 
status, muscle strength, pulmonary function, and biochemi-
cal parameters (Fig. 1A). Peripheral blood lymphocytes and 
anti-interferon (IFN)-α antibodies were elevated, but CD19+ 
and CD20+ mature B cells were absent. CD4+, CD8+, CD4−/
CD8−, mature naive CD4+ and CD8+ T cells were increased 
with an inverted CD4/CD8 ratio.
She received three more doses of cixutumumab before 
the disease progression. During steroid taper, she was diag-
nosed with pure red cell aplasia and amegakaryocytic throm-
bocytopenia based on hypoproliferative anemia (hemoglobin 
10 g/dl), thrombocytopenia (platelet count 13,000/ul), and 
cellular marrow with absent megakaryocytes and severe ery-
throid hypoplasia. Hematological parameters normalized on 
cyclosporine A (Fig. 1B) and thymoma remained stable.
DISCUSSION
The spectrum of thymoma-associated auto-immune 
paraneoplastic syndromes include myasthenia gravis (seen 
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TABLE 1.  Results of Pertinent Diagnostic Tests at 
Presentation
Variable Laboratory Value (Normal)
White blood cell count 14.3 (3.9–10K/ul)
CD4+ T cells 3324 (359–1565/uL)
CD8+ T cells 3389 (178–853/uL)
CD4−/CD8− T cells 375 (18–185/uL)
Mature naive (CD45RA+/CD3+)  
CD4+ T cells
2466 (82–755/uL)
Mature naive (CD45RA+/CD3+)  
CD8+ T cells
3093 (51–572/uL)
CD4/CD8 ratio 0.98
Eosinophils 15 (0.7–5.8%)
CPK 4927 (38–252 U/L)
CPK-MB fraction 5% (0–3%)
Aldolase 118 (1–6 U/L)
AST 303 (9–34 U/L)
ALT 381 (6–41 U/L)
IgG 364 (642–1730 mg/dl)
IgA 42 (91–499 mg/dl)
IgM < 21 (34–342 mg/dl)
C-reactive protein 13.8 (< 3 mg/L)
Anti-acetylcholine receptor Ab 0.19 (< 0.02 nmol/L)
Cardiac troponin I 0.880 (< 0.045 ng/ml)
Electrocardiograph Nonspecific ST segment T wave 
abnormalities
Echocardiogram Normal left ventricular ejection fraction 
and no wall motion abnormalities
Cardiac MRI Atypical delayed enhancement of basal 
inferolateral and mid anterolateral 
walls, suggestive of myocarditis
Repetitive nerve  
stimulation test
No change in compound muscle action 
potential amplitude with repetitive 
nerve stimulation
MRI of thighs Symmetric scattered foci of increased 
signal intensity in and adjacent to 
the muscles consistent with myositis 
and deep fascial inflammation
Electromyography No evidence of active denervation 
or membrane irritability (test 
done after patient had been on 
methylprednisone for 2 days)
Pulmonary function tests Very severe restrictive pattern, decreased 
diffusion capacity, and increased ratio 
of residual volume/total lung capacity, 
suggestive of air trapping
Ig, immunoglobulin; CPK, creatinine phosphokinase; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; MRI, magnetic resonance imaging.
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in 30–45% of the patients), immune-mediated cytopenias, 
hypogammaglobulinemia, neurologic syndromes, and less 
commonly polymyositis, hepatitis, and myocarditis. Although 
myasthenia gravis with auto-immune involvement of another 
organ system may be found in up to 15% of the patients with 
thymoma, the involvement of more than one organ system, as 
in this case, is rare.
The etiology of thymoma-associated autoimmune phe-
nomena is unclear. Our patient had a complete absence of 
B cells and markedly abnormal T cell distribution. Lack of 
thymocyte passage through the medulla, where self-tolerance 
is induced, may result in thymoma-derived immature T cells 
and autoreactive T-cell clones. Other potential mechanisms 
include the increased frequency of mutations in thymoma-
derived T cells because of the high turnover rate of corti-
cal thymocytes2 and reduced numbers of T regulatory cells, 
which have inhibitory effects on the antigen-specific activa-
tion of naive autologous T cells.3 In a subset of the patients, 
defects in autoimmune regulatory (AIRE) gene may play a 
role. The AIRE protein is mainly expressed in the medullary 
thymic epithelial cells where it promotes the thymic expres-
sion of self-antigens and regulates the negative selection of 
self-reactive T cells.4 AIRE mutations underlie the APECED 
syndrome (autoimmune polyendocrinopathy candidiasis 
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FIGURE 1.  Trends in aspartate ami-
notransferase (AST), alanine transami-
nase (ALT), creatine phosphokinase 
(CPK), troponin I (A), hemoglobin 
and platelet count (B). The arrows 
indicate the time points at which 
cixutumumab was administered.
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ectodermal dystrophy) which shares autoimmune manifesta-
tions and anti-interferon autoantibodies with thymoma associ-
ated autoimmune syndromes.5
Nine of the 37 (24%) patients with thymoma developed 
new or worsening autoimmune disorders after receiving cixutu-
mumab in the phase II trial,1 including three of the five patients 
who had partial responses. The association between the auto-
immune manifestations with the response is possibly due to a 
modulation of the thymic immune mileu by cixutumumab or an 
egress of dysfunctional T cells to the periphery as a result of the 
tumor shrinkage. Although thymoma itself has a strong associa-
tion with the autoimmune phenomena, the potential etiological 
role of cixutumumab needs further evaluation.
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